{
    "nct_id": "NCT03088527",
    "official_title": "A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer",
    "inclusion_criteria": "* Progressive metastatic or locally advanced or metastatic breast cancer.\n* Clinically confirmed as postmenopausal.\n* Eastern Cooperative Oncology Group (ECOG) score of 0 to 1 at screening.\n\nKey\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* HER2 positive patients by local laboratory testing.\n* Triple negative breast cancer.\n* Any chemotherapy within the 28 days prior to the first dose of study drug.\n* Any non-chemotherapy anti-cancer drug less than 5 half-lives (30 days for biologics) or less than 14 days for small molecule therapeutics, or if half-life is not known.\n* Tamoxifen and aromatase inhibitors within 14 days prior to the first dose of study drug.\n* Fulvestrant within 30 days prior to first dose of study drug.\n* Any investigational drug therapy within 5 half-lives of the previous investigational study drug or 30 days, whichever is shorter.\n* Radiation therapy for breast cancer within 2 weeks of dosing and planning to have radiation therapy during participation in this study.\n* Known history of human immunodeficiency virus infection (HIV) or hepatitis C or active hepatitis B infection, unless the patient was diagnosed >10 years prior to enrollment and no evidence of active liver disease.\n* Currently taking testosterone, methyltestosterone, oxandrolone (Oxandrin), oxymetholone, danazol, fluoxymesterone (Halotestin), or testosterone-like agents.\n* Untreated or uncontrolled brain metastasis.\n* Diagnosed with or treated for cancer within the previous 2 years, other than breast cancer or non-melanoma carcinoma of the skin.\n* Pregnant and nursing females.",
    "miscellaneous_criteria": "Key"
}